The hypothesis that PLCγ1 could work as a potential therapeutic target for gliomas is also supported by a recent work that claims an association between PLCγ1 overexpression, tumor progression, and negative prognosis in patients characterized by IDH-wildtype lower-grade gliomas (LGGs) [41]. Here, PLCG1 is linked to central nervous system cancer.